TY - JOUR T1 - Statistical Design and Analysis of Diagnostic Tests for Mutating Viruses JF - medRxiv DO - 10.1101/2021.04.07.21254917 SP - 2021.04.07.21254917 AU - Yang Han AU - Yujia Sun AU - Jason C. Hsu AU - Thomas House AU - Nick Gent AU - Ian Hall Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/04/2021.04.07.21254917.abstract N2 - Mutations in the SARS-CoV-2 virus has given rise to concerns how diagnostic tests, treatments, and vaccines are affected. This article shows the presence of mutations in the Spike gene (S gene), which is prone to mutation, can be detected not only at the epidemiological (aggregate) level but in fact at the patient level using standard TaqPath PCR (polymerase chain reaction) test. However, only sequencing can reveal precise mutations at the amino acids level. Since PCR testing capacity far exceeds sequencing capability, patient level calling by our algorithm offers an efficient path toward targeted sequencing of cases infected by mutants, for discovering the actual mutations. Overcoming patient-to-patient variability by conditioning on an internal control, our statistical methodology classifies each patient as infected by wildtype or by some mutant strain(s) with reasonable accuracy. Besides adding a new tool for tracking emerging mutations epidemiologically, patient level calling is also important for treatment purpose, as there is evidence that some antibody treatments are less active in neutralizing the SARS-CoV-2 virus against certain mutant strains. Our algorithm can be continuously retrained as the SARS-CoV-2 virus evolves.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors: UK Research and Innovation (UKRI), National Institute for Health Research (NIHR), the Alan Turing Institute for Data Science and Artificial Intelligence and the University of Manchester.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A. No clinical trial involved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo publicly accessible data is available for sharing. ER -